HUTCHMED discloses insolvency of company linked to its chairman

HUTCHMED (China) Limited disclosed on August 18, 2026 that its board was notified of insolvency proceedings involving S.D. Sight Diagnostics Ltd., a company where Chairman and Non-executive Director Dan Eldar had previously served as a board member.

According to the company, S.D. Sight is a private Israeli medical device company based in Tel Aviv that is developing a computer vision platform for diagnosing blood diseases.¹ Dr. Eldar served as a director of the company from December 20, 2018 to March 18, 2026.¹ A related entity, Hutchison Water Israel E.P.C Ltd, where Dr. Eldar serves as an executive director, held roughly a 9.98% stake in S.D. Sight and had put Dr. Eldar forward for the board seat.¹ HUTCHMED noted that neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is part of the HUTCHMED group.¹

On the timeline of the proceedings, the company said a request to begin insolvency proceedings for S.D. Sight was submitted on April 12, 2026, that a Tel Aviv-Jaffa district court ordered the proceedings to start on May 24, 2026, and that a trustee was named on May 28, 2026.¹ The proceedings were still underway, and the company said it did not yet know the eventual outcome.¹

Public filings with Israel's Insolvency Proceedings Commissioner put the amount involved at approximately NIS3,057,876, or about US$1,019,292.¹

Because the trustee appointment fell within twelve months of Dr. Eldar leaving the S.D. Sight board, HUTCHMED said the disclosure was required under AIM listing rules covering changes in information about directors.

The company stated that since the proceedings do not involve HUTCHMED or its businesses, the board believes there is no impact on the group's operations.¹